VEGFA and cancer: Skewing of the DC phenotype is driven by a complex interplay of factors, with key drivers being anti-inflammatory cytokines, predominantly secreted by tumor cells and cancer-associated fibroblasts, such as IL-6, IL-10, vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β.